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Background:  Patients on chronic clopidogrel therapy (CCT) presenting with acute coronary syndrome (ACS) have a poor prognosis possibly due 
to low response to clopidogrel. Large randomized studies evaluating clopidogrel reloading are lacking. This study aimed to evaluate whether there is 
additional benefit of reloading with clopidogrel in patients who present with ACS.
Methods:  A cohort of 2137 patients on CCT (> 5 days) who presented with ACS and received at least 1 stent were identified and were followed 
clinically up to 1 year. 1334 patients were reloaded with ≥ 300 mg of clopidogrel and 803 patients were not reloaded. All patients continued CCT 
of 75 mg /day in addition to aspirin. The decision to reload was at the discretion of the operator. Patients with cardiogenic shock and vein graft 
intervention were excluded. 
Results:  The baseline characteristics were similar except No-reload group were older, had more vascular and renal disease, and heparin use. (see 
table). The composite major in-hospital complications and in-hospital bleeding rates (major and minor) were similar. MACE at 1 year was similar in 
both groups even after adjustment of differences in baseline characteristics. (HR:0.83,[0.57-1.22], p=0.351)
Conclusions: Patients on chronic clopidogrel therapy who present with ACS have similar in-hospital outcomes regardless of clopidogrel reloading. 
Clopidogrel reloading, although safe, does not impact in-hospital or long term clinical events.
Baseline Characteristics
Reload 
(n=1334)
No Reload
(n=803)
p 
value
Age 63.8±12.4 65.2 ±11.8 0.010
African american, % 31.8 25.8 0.003
Diabetes, % 41.6 41.3 0.907
History of MI, % 38.5 44.7 0.008
PVD, % 17.3 21.8 0.010
Chronic kidney disease, % 15.3 20.8 0.001
Presentation with AMI, % 19.5 19.2 0.847
Procedure Characteristic n=2283 n=1476
Number of diseased vessels 1.77 ± 0.83 1.97 ± 0.86 0.001
Restenotic lesion, % 7.3 9.8 0.006
Drug eluting stent, % 88.7 84.2 0.001
Heparin use, % 10.5 13.6 0.032
Bivalirudin use, % 83.6 79.5 0.016
Outcomes
Reload
(n=1334)
No Reload
(n=803)
p value
Major In-hospital Complications (MIC), % (Death,
QWMI, CABG)
1.0 0.7 0.589
In-hospital minor bleeding, % 2.10 2.74 0.376
In-hospital major bleed (IHMB), % (GI bleeding,HCT drop
>15, hematoma >4cm)
1.0 1.1 0.872
MACE at 1 year,%
(Death, MI, TVR)
16.1 20.2 0.058
Death 6.1 7.1 0.467
MI 2.0 1.9 0.952
TVR 10.8 13.8 0.102
Stent Thrombosis at 1 year, % 1.1 1.7 0.376
